Revolution Medicines, Inc.

RVMD Healthcare Biotechnology

Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.

Revenue
+1,188.7%
EPS
−18.0%
Free cash flow
−99.1%
Total debt
+322.7%

Quarter to September 2026, against a year earlier

194.18 16.53 +9.30%
Market cap
$38.1B
P/E
0.0×
Fwd P/E
−11.9×
Dividend yield
—
F-score
4/9
Altman Z
7.73
Beneish M
−4.29
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26 From the 10-Q filed 4 Nov
ROE

+8 more TTM periods

(58.07%) (76.67%) (79.09%) (93.56%)
ROA
(46.06%) (59.39%) (52.37%) (57.07%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(62.23%) (80.23%) (47.68%) (52.90%)
Average Days of Receivables
— — — 0.00
Free Cash Flow per Share
(4.81) (5.41) (5.84) (6.70)
Free Cash Flow
(913.73) (1,071.73) (1,232.13) (1,440.82)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 4 Nov 2026